CA3096687A1 - Methods for preparing substituted pyridinone-containing tricyclic compounds - Google Patents

Methods for preparing substituted pyridinone-containing tricyclic compounds Download PDF

Info

Publication number
CA3096687A1
CA3096687A1 CA3096687A CA3096687A CA3096687A1 CA 3096687 A1 CA3096687 A1 CA 3096687A1 CA 3096687 A CA3096687 A CA 3096687A CA 3096687 A CA3096687 A CA 3096687A CA 3096687 A1 CA3096687 A1 CA 3096687A1
Authority
CA
Canada
Prior art keywords
contacted
methoxypropoxy
methoxy
salt
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3096687A
Other languages
English (en)
French (fr)
Inventor
Shuai Chen
Bruce D. Dorsey
Dimitar B. Gotchev
Duyan Nguyen
Mahesh Kumar PALLERLA
Ganapati Reddy Pamulapati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of CA3096687A1 publication Critical patent/CA3096687A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00—Introduction of protecting groups or activating groups, not provided for in the preceding groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3096687A 2018-04-12 2019-04-11 Methods for preparing substituted pyridinone-containing tricyclic compounds Pending CA3096687A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862656605P 2018-04-12 2018-04-12
US62/656,605 2018-04-12
US201862700048P 2018-07-18 2018-07-18
US62/700,048 2018-07-18
PCT/US2019/027004 WO2019200109A1 (en) 2018-04-12 2019-04-11 Methods for preparing substituted pyridinone-containing tricyclic compounds

Publications (1)

Publication Number Publication Date
CA3096687A1 true CA3096687A1 (en) 2019-10-17

Family

ID=68163316

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096687A Pending CA3096687A1 (en) 2018-04-12 2019-04-11 Methods for preparing substituted pyridinone-containing tricyclic compounds

Country Status (9)

Country Link
US (1) US11505551B2 (enExample)
EP (1) EP3773584A4 (enExample)
JP (1) JP2021521154A (enExample)
KR (1) KR20200142529A (enExample)
CN (1) CN112839654A (enExample)
AU (1) AU2019252441A1 (enExample)
CA (1) CA3096687A1 (enExample)
TW (1) TW202010499A (enExample)
WO (1) WO2019200109A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128044B2 (en) 2018-08-28 2024-10-29 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78491B (enExample) 1982-03-24 1984-09-27 Nat Res Dev
JPS60197684A (ja) 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔ａ〕キノリジン誘導体およびその塩
ITFI970193A1 (it) 1997-08-01 1999-02-01 Applied Research Systems Uso di derivati benzo(c) chinolizinici come regolatori della crescita delle piante e composizioni ad uso agricolo che contengono tali
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US8063037B2 (en) 2007-05-07 2011-11-22 N. V. Organon Progesterone receptor modulators
US8835461B2 (en) * 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
PE20160686A1 (es) * 2014-01-30 2016-07-23 Hoffmann La Roche Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
CN106459032B (zh) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的新的二氢喹嗪酮类
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
EP3325477B1 (en) 2015-07-21 2019-05-01 H. Hoffnabb-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017016960A1 (en) * 2015-07-24 2017-02-02 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
CN109071447B (zh) 2016-02-19 2022-04-22 诺华股份有限公司 四环吡啶酮化合物作为抗病毒剂
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2018019297A1 (zh) 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
CA3031063A1 (en) 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Benzo-quinolizin-2oxo carboxylic acid derivatives for the treatment of hbv infection
CN107759585A (zh) 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
TW201811788A (zh) 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
JP7113009B2 (ja) 2016-11-07 2022-08-04 アービュタス バイオファーマ コーポレイション 置換ピリジノン含有三環式化合物およびそれを使用する方法
CN106810548B (zh) 2017-01-13 2019-02-15 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物

Also Published As

Publication number Publication date
WO2019200109A1 (en) 2019-10-17
US20210032246A1 (en) 2021-02-04
EP3773584A1 (en) 2021-02-17
EP3773584A4 (en) 2022-01-05
TW202010499A (zh) 2020-03-16
US11505551B2 (en) 2022-11-22
AU2019252441A1 (en) 2020-10-22
JP2021521154A (ja) 2021-08-26
KR20200142529A (ko) 2020-12-22
CN112839654A (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
JP6761448B2 (ja) アザインドールを作製するための方法および中間体
TWI658042B (zh) 雜環化合物的合成
JP5636054B2 (ja) Ｈｉｖインテグラーゼ阻害活性を有する化合物の製造方法
CN102482219B (zh) 吡喃酮和吡啶酮衍生物的制备方法
US6444820B1 (en) Process for the manufacture of camptothecin derivatives
CN118434748A (zh) 一种六元并六元化合物、制备方法、药物组合物和应用
BRPI0707945A2 (pt) derivados de 3-deazapurina como modulares de tlr7
TW202208370A (zh) 嘧啶基-3,8-二氮雜雙環[3.2.1]辛烷基甲酮衍生物及其鹽之製備
EP1999133A2 (en) Process for preparation of hiv protease inhibitors
CN113620931A (zh) 一种雄激素受体抑制剂及其用途
WO2007148780A1 (ja) ６－（複素環置換ベンジル）－４－オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
US20160257667A1 (en) Synthesis of intermediates in the preparation of alk inhibitor
JP2022513151A (ja) 重水素化大環状化合物の調製方法
CN111825700A (zh) 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物
WO2011004389A2 (en) An improved process for the preparation of elvitegravir
US20230278960A1 (en) Novel acridinium salt and method for producing same
US11505551B2 (en) Methods for preparing substituted pyridinone-containing tricyclic compounds
CZ254396A3 (en) Process for preparing epoxide
JP4742868B2 (ja) （２ｒ）−２−プロピルオクタン酸の製造方法、その中間体
JP2009073743A (ja) 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物
CN103664943B (zh) 嘌呤衍生物的制备方法及其中间体和应用
WO2016023522A2 (en) Substituted phosphoramidate compounds and uses thereof
WO2026093943A1 (en) Chemical process for preparing phenylpiperidinyl indole derivatives
TWI588146B (zh) 恩替卡韋的合成方法及其中間體化合物
TW201925178A (zh) 阿卡替尼（acalabrutinib）之製造方法

Legal Events

Date Code Title Description
B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20240723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250926

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260525

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703